Tyrosine Kinase

A phase 2 trial found the oral tyrosine kinase 2 inhibitor PF-06826647 to be safe and efficacious in the treatment of moderate to severe plaque psoriasis.

In this video Aaron T. Gerds, MD, assistant professor in medicine at the Cleveland Clinic Taussig Cancer Institute, discusses a new irreversible FLT3 inhibitor that was tested in a first-in-human study.

Bruton tyrosine kinase inhibitor rilzabrutinib, in association with longer treatment, showed improved clinical activity in patients with pemphigus, according to a study reported at the American Academy of Dermatology virtual meeting.

Blinatumomab appeared to confer better outcomes than standard of care among adults with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia, according to results of a propensity score analysis published in Cancer.